Targeting cancer at the cellular level.
Novel cancer & infectious-disease therapeutics built on a precision fusion-protein platform.
pDNA · Fusion proteins · LNP delivery
Ask XFBiologics
Curious about our platform? Ask a question or tap a topic below.
Platform breadth
A precision platform, validated broadly in the lab
Figures reflect the scope of our preclinical research program — not clinical outcomes.
0
cancer cell lines showing apoptosis in preclinical testing
Validated by Eurofins Panlabs
0
oncology indications in the pipeline
0
infectious-disease programs
0-yr
issued patents (USPTO & EU)
OTM001 for breast cancer, including TNBC
Our lead biologic candidate targets breast cancer — including triple-negative breast cancer (TNBC), a subtype with limited effective treatment options. OTM001 is investigational and has completed preclinical proof-of-concept.
Platform at a glance
One platform, engineered for precision
Fusion-protein modality
Patented, monoclonal-antibody-derived therapeutic leads engineered for tumor selectivity.
pDNA + LNP delivery
Plasmid DNA encapsulated in lipid nanoparticles — the class of system behind mRNA vaccines, built around DNA.
Tumor-selective design
Candidates designed to act on cancer cells while sparing tested normal-cell controls in preclinical models.
Broad pipeline
Eleven oncology indications and four infectious-disease programs from a single platform.
Why it matters
The need is growing
Public industry data underscores the scale of the challenge our platform is built to address.
~20M → ~35M
Global cancer cases projected to rise from ~20 million (2022) toward ~35 million by 2050.
Source: AACR Cancer Progress Report 2024
~$223B
Global oncology spending in 2023 — the scale of investment in cancer care worldwide.
Source: IQVIA Global Oncology Trends 2024